Souhaitez-vous accéder aux communiqués récents ?

ASTRAZENECA PROVIDES TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL IN ADVANCED GASTRIC CANCER 18 May 2016 AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel...

ASTRAZENECA ANNOUNCES POSITIVE RESULTS FROM BENRALIZUMAB PHASE III PROGRAMME IN SEVERE ASTHMA Benralizumab first AstraZeneca respiratory biologic to complete Phase III 17 May 2016 AstraZeneca today...

SELUMETINIB granted Orphan Drug Designation in the US for ADJUVANT treatment of Differentiated thyroid cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Publication of Final Terms in relation to the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION AstraZeneca launches and prices bond issues of...

Publication of Prospectus Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK...

AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola...

ASTRAZENECA COMPLETES ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS AstraZeneca today announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company...

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016 Results of Annual General Meeting held on 29 April 2016 AstraZeneca PLC announced the results of the voting at its Annual General Meeting today.  As...

POSITIVE CHMP OPINION FOR CAZ AVI IN THE EU FOR SERIOUS BACTERIAL INFECTIONS AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...